Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United States
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Introduction: We estimate societal value of a disease‐modifying Alzheimer's disease (AD) treatment that reduces progression by 30% in early stages. Methods: Using the International Society for Pharmacoeconomics and Outcomes Research value flower as framework, we estimate gross societal value, that is, not including treatment cost, from avoided medical and social care costs, productivity and quality‐adjusted life‐years (QALY) gains for patients and caregivers, adjusting for severity of disease, value of financial insurance, and value of insurance for currently unafflicted adults with a Markov model. Results: Predicted societal value from 2021 until 2041 is $2.62 trillion for the overall afflicted US population and $986 billion for the 2021 prevalent cohort or $134,418 per person, with valuation of patients’ QALY gains (63%) and avoided nursing‐home costs (20%) as largest components. Delays in access because of health system capacity constraints could reduce realized value between 52% and 69%. The value of insurance for the unafflicted is $4.52 trillion or $18,399 on average per person. Discussion: With a total of $5.5 trillion, the projected gross societal value of a hypothetical AD treatment is substantial, which may help to put the cost of treatment into perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Cost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847
Tax Avoidance and the Deadweight Loss of the Income Tax
Feldstein, M. (1999) · Review of Economics and Statistics · doi:10.1162/003465399558391 · Cited by 816
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
Alzheimer’s disease drug development pipeline: 2021
Cummings, J., Lee, G., Zhong, K., Fonseca, J., & Taghva, K. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12179 · Cited by 539
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00838-z · Cited by 224
Schaller, S., Mauskopf, J., Kriza, C., Wahlster, P., & Kolominsky-Rabas, P. L. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4198 · Cited by 215
Liu, J., Hlavka, J., Hillestad, R., & Mattke, S. (2017) · doi:10.7249/rr2272 · Cited by 98
Self-citationInternational, R., & Lines, L. (2014) · doi:10.3768/rtipress.2014.rr.0024.1412 · Cited by 89
Cited by
Societal Costs of Dementia: 204 Countries, 2000–2019
Lastuka, A., Bliss, E., Breshock, M. R., Iannucci, V. C., Sogge, W., Taylor, K. V., Pedroza, P., & Dieleman, J. L. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240163 · Cited by 41
Using Alzheimer's disease blood tests to accelerate clinical trial enrollment
Schindler, S. E., Li, Y., Li, M., Despotis, A., Park, E., Vittert, L., Hamilton, B. H., Womack, K. B., Saef, B., Holtzman, D. M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12754 · Cited by 38
Estimating prevalence of early symptomatic Alzheimer's disease in the United States
Spargo, D., Zur, R., Lin, P., Synnott, P., Klein, E., & Hartry, A. (2023) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12497 · Cited by 9
Metadata
- Authors
- Prados, M. J., Liu, Y., Jun, H., Lam, J., & Mattke, S.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2022-01
- Volume
- 18
- Issue
- 1
- Pages
- 142-151
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4211104519
- Cited by
- 42
- References
- 13
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.